Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Arris Pharmaceutical Articles

Many US Companies Go Into The Black For 2nd Qtr

5 August 1998

BM-S & Pharmacopeia In $40 Million Alliance

4 December 1997

Appointment At Arris

27 November 1997

Arris & Sequana Merge In $166 Million Deal

6 November 1997

Arris Plays Down Negative Asthma Trial

2 October 1997

Arris/Merck Join Forces On Protease Inhibitors

25 November 1996

US Biopharma Cos Report 3rd-Qtr Financial Results

11 November 1996

Bayer Opts Into Arris' Tryptase Inhibitor For Asthma

21 October 1996

Arris' Promising Data With Asthma Drug

30 September 1996

Biopharmaceutical Firms Report On 2nd Qtr

12 August 1996

Arris And SKB To Investigate Delta Technology

22 July 1996

Another Angle On Asthma; Arris Pharmaceuticals

27 May 1996

US Corporate Quarterly Results Round-Up

13 May 1996

Tryptase Inhibition For Asthma

6 May 1996

Important Developments For US Biotechnology Cos

19 February 1996

Arris Pharmaceutical / Pharmacia & Upjohn collaboration extended

12 February 1996

Arris/Pharmacia: serine protease inhibitor deal

11 September 1995

Arris Pharmaceuticals Collaboration With Bayer

5 December 1994

ARRIS PHARMA RESEARCH

3 May 1993

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS